Boulding Mark Elliott 4
4 · PTC THERAPEUTICS, INC. · Filed Jun 22, 2026
Research Summary
AI-generated summary of this filing
PTC Therapeutics (PTCT) Exec. VP & CLO Mark Boulding Exercises Options, Sells Shares
What Happened
- Mark Elliott Boulding, Executive Vice President and Chief Legal Officer of PTC Therapeutics (PTCT), exercised stock options to acquire 10,522 shares (8,510 + 2,012) at $46.54 per share (total exercise cost ~$489,693) on June 17, 2026. On the same day he sold 10,462 shares in open-market transactions for aggregate proceeds of about $822,868. Net of the exercise cost, the transactions produced roughly $333,175 in proceeds before taxes, withholding and fees. The filing shows conversion/disposition entries for the derivatives related to the exercise.
Key Details
- Transaction date: June 17, 2026 (Form 4 filed June 22, 2026 — filing was late relative to the two-business-day requirement).
- Exercises: 8,510 shares @ $46.54 = $396,055; 2,012 shares @ $46.54 = $93,638.
- Open-market sales (weighted averages / ranges): 6,600 @ $78.50 = $518,100 (sales executed in $78.00–$78.99 range per footnote); 1,850 @ $79.24 = $146,594 ($79.00–$79.49 range); 1,703 @ $78.50 = $133,686 ($79.00–$79.48 range noted); 309 @ $79.25 = $24,488.
- Net effect: acquired 10,522 shares via option exercise and sold 10,462 shares — a net increase of 60 shares.
- Notable footnotes: sales were made pursuant to a written Rule 10b5-1 plan adopted Sept 10, 2025 (F1). Footnotes F2–F4 explain weighted-average sale prices and trade price ranges. F5 describes the option grant (Jan 3, 2025) and vesting schedule.
- Derivative entries at $0.00 reflect conversion/exercise reporting of the options (transaction code M).
- Filing timeliness: Report filed June 22 for June 17 transactions — appears to be late (Form 4 normally due within two business days).
Context
- This was an option exercise with immediate or near-immediate open-market sales of most of the acquired shares — effectively a cash-raising or tax-liability management move rather than a straightforward buy signal. The presence of a 10b5-1 plan indicates the sales were pre-arranged. As always, insider sales can be routine (diversification, tax withholding, option exercise) and should not be interpreted alone as a view on the company’s fundamentals.
Insider Transaction Report
Form 4
Boulding Mark Elliott
EXEC. VP AND CLO
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-06-17$46.54/sh+8,510$396,055→ 113,722 total - Sale
Common Stock
[F1][F2]2026-06-17$78.50/sh−6,600$518,100→ 107,122 total - Sale
Common Stock
[F1][F3]2026-06-17$79.24/sh−1,850$146,594→ 105,272 total - Exercise/Conversion
Common Stock
[F1]2026-06-17$46.54/sh+2,012$93,638→ 107,284 total - Sale
Common Stock
[F1][F2]2026-06-17$78.50/sh−1,703$133,686→ 105,581 total - Sale
Common Stock
[F1][F4]2026-06-17$79.25/sh−309$24,488→ 105,272 total - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F5]2026-06-17−8,510→ 32,950 totalExercise: $46.54Exp: 2035-01-02→ Common Stock (8,510 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F5]2026-06-17−2,012→ 30,938 totalExercise: $46.54Exp: 2035-01-02→ Common Stock (2,012 underlying)
Footnotes (5)
- [F1]This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025.
- [F2]This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $78.00 to $78.99 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- [F3]This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $79.00 to $79.49 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- [F4]This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $79.00 to $79.48 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- [F5]This option was granted on January 3, 2025, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2026, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2026.
Signature
/s/ Avraham S. Adler, Attorney-in-Fact|2026-06-22